Results 21 to 30 of about 636,170 (221)
Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
Journal of Translational Autoimmunity, 2022 Bruton tyrosine kinase (BTK) is involved in a multifarious inflammatory and autoimmune process. As a result, BTK has emerged as a promising novel remedial target for amalgamated autoimmune diseases.
Piyu Parth Naik
doaj +1 more source
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
Clinical Hematology International, 2022 The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease.
Obada Ababneh +4 more
doaj +1 more source
Pharmaceuticals, 2023 Bruton’s tyrosine kinase (BTK) is a critical component in B-cell receptor (BCR) signaling and is also expressed in haematogenic and innate immune cells. Inhibition of BTK hyperactivity is implicated in B-cell malignancies and autoimmune diseases.
Asim Najmi +8 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Background: Bruton’s tyrosine kinase (BTK) inhibitors are commonly used in the targeted therapy of B-cell malignancies. It is reported that myelosuppression and fungal infections might occur during antitumor therapy of BTK inhibitors, therefore a ...
Lu Chen +5 more
doaj +1 more source
Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib.
PLoS ONE, 2023 Bruton's tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-
David Y Lin, Amy H Andreotti
doaj +2 more sources
Cross Fire: BTK Inhibitors Alone or in Combination are the Best Frontline Therapy for CLL
Hematology/Oncology and Stem Cell Therapy, 2023 BTK (Bruton's tyrosine kinase) inhibitors are highly effective front-line therapy for CLL (chronic lymphocytic leukemia) due to high response rates and prolonged progression-free survival, even in patients with high-risk disease features.
Theo Sottero, Farrukh T. Awan
doaj +1 more source
Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors
Journal of Enzyme Inhibition and Medicinal Chemistry, 2022 Bruton tyrosine kinase (BTK) is linked to multiple signalling pathways that regulate cellular survival, activation, and proliferation. A covalent BTK inhibitor has shown favourable outcomes for treating B cell malignant leukaemia.
Tony Eight Lin +10 more
doaj +1 more source
A Fast and Clean BTK Inhibitor [PDF]
Journal of Medicinal Chemistry, 2020 Bruton's tyrosine kinase (BTK) is a major drug target for B-cell related malignancies; however, existing BTK inhibitors approved for cancer treatment have significant off-targets that limit their use for autoimmune and inflammatory diseases. Remibrutinib (LOU064) is a novel covalent BTK inhibitor that binds an inactive BTK conformation, which affords ...
Ronen Gabizon, Nir London
openaire +2 more sources
The chemical structures of irreversible BTK inhibitors.
, 2023 The chemical structures of irreversible BTK inhibitors.
Amy H. Andreotti (366314) +1 more
core +1 more source
, 2008 Activated mast cells are a major source of the eicosanoids PGD(2) and leukotriene C(4) (LTC(4)), which contribute to allergic responses. These eicosanoids are produced following the ERK1/2-dependent activation of cytosolic phospholipase A(2), thus ...
Gilfillan, Alasdair M. +5 more
core +2 more sources